

MYCOTOXINS AND ENDOTOXINS BINDING BY AN INNOVATIVE ANTI-MYCOTOXINS AGENT

Riahi, I.¹, Sadurní, M.¹, Trabalón, L.¹, Sattar, A.A.², Jackson, S.K.²

¹Technical Department, BIÖNTE Nutrition, Reus, Spain

²Molendotech Limited, Brixham Laboratory, Blackball Lane, Freshwater Quarry, Brixham TQ5 8BA, UK

insaf.riahi@bionte.com

INTRODUCTION


Mycotoxins are secondary metabolites produced by toxigenic fungus that contaminate raw materials and feedstuffs worldwide. They are considered an **important risk for animal health**. In fact, mycotoxins **disrupt the gut barrier**, leading to **bacterial translocation** and subsequent **negative effects by the endotoxins (lipopolysaccharides, LPS)**.

OBJECTIVE


The aim of the present study was to evaluate the *in vitro* efficacy of an anti-mycotoxins agent that contains selected binding material and natural extracts besides an exclusive combination of yeasts, against the most important mycotoxins, and endotoxins from *Escherichia coli* and *Salmonella*.

MATERIALS AND METHODS


In vitro efficacy trial – Mycotoxins



In vitro endotoxins binding study



RESULTS



CONCLUSIONS

The anti-mycotoxins agent tested in the present study has a **high *in vitro* efficacy** against a **wide spectrum of mycotoxins**, including T-2 mycotoxin from trichothecenes group, and **endotoxins** from *E. coli* O111:B4 and *Salmonella Typhimurium*.